Beranda › Kanker Payudara Triple-Negatif › Minnesota › Minneapolis
Uji klinis Kanker Payudara Triple-Negatif di Minneapolis, MN
8 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Minneapolis (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
PRE-ISPY Phase I/II Oncology Platform Program
Menerima pesertaFase 1/2
- University of Minnesota Masonic Cancer Center, Minneapolis
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Menerima pesertaFase 3
- Allina Health Cancer Institute ( Site 0069), Minneapolis
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Menerima pesertaFase 3
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park · 5 mi jauhnya
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Menerima pesertaFase 3
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- Metro Minnesota Community Oncology, Saint Louis Park · 5 mi jauhnya
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, Minneapolis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Menerima pesertaFase 2/3
- Local Institution - 0372, Minneapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Menerima pesertaFase 1
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- University of Minnesota, Minneapolis
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park · 5 mi jauhnya
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Studi lain di Minneapolis
- Kanker Paru Non-Sel Kecil27 studi
- Kanker Payudara27 studi
- Kanker Ovarium24 studi
- Kanker Prostat23 studi
- Kanker (semua jenis)22 studi
- Gagal Jantung21 studi
- Leukemia Mieloid Akut20 studi
- Kanker Paru20 studi
- Kanker Kolorektal19 studi
- Kanker Endometrium18 studi
- Penyakit Parkinson17 studi
- Penyakit Kardiovaskular15 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.